AI-generated analysis. Always verify with the original filing.
Harvard Bioscience, Inc. held a Special Meeting of Stockholders on March 6, 2026, where shareholders approved a Reverse Stock Split Proposal. The Board approved a 1-for-10 reverse stock split effective March 13, 2026 at 4:30 p.m. ET, reducing outstanding Common Stock from approximately 44,179,894 to 4,471,989 shares while maintaining 80,000,000 authorized shares.
Event Type
Disclosure
Mandatory
Variant
8-K
Submission of Matters to a Vote of Security Holders. On March 6, 2026, Harvard Bioscience, Inc. (the “Company”) held its previously announced Special Meeting of
of this Form 8-K (including Exhibit 99.1 attached hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amen
Other Events. Following stockholder approval of the Reverse Stock Split Proposal, the Board approved a final reverse stock split ratio of 1-for-10. Following su
Financial Statements and Exhibits. (d) Exhibits. EXHIBIT NUMBER EXHIBIT DESCRIPTION 3.1 Certificate of Amendment to the Second Amended and Restated Certificate